Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 66   

Articles published

PFE 36.07 +0.33 (0.92%)
price chart
Pfizer sued by retailers for generic Lipitor delay
Five big U.S. retailers filed an antitrust lawsuit against Pfizer Inc and India's Ranbaxy Laboratories Ltd on Thursday, accusing them of conspiring to delay sales of generic versions of Lipitor, the best-selling drug in history.
Pharmacies Sue Pfizer Over Lipitor  Wall Street Journal
Retailers sue Pfizer, charge generic Lipitor delay
Pfizer yanks breast, colon claims for Centrum vitamins
"The company disagrees with CSPI's concerns, but has agreed to make these changes in order to fully resolve the issues raised by the organization," Pfizer said in a statement provided on Thursday. A company spokesman declined to elaborate when asked ...
Pfizer Agrees To Change Centrum Vitamin Health Claims  RedOrbit
Pfizer to remove "breast health" and "colon health" ...  CBS News
Verastem Acquires Clinical-Stage FAK Inhibitor from Pfizer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced an agreement with Pfizer for ...
In deal flurry, Verastem vaults to PhII on Pfizer cancer drug pact  FierceBiotech
Verastem Inks Separate Deals for Wnt and FAK Inhibitors  Genetic Engineering News
Pfizer Posts Strong Profits, Faces Strong Headwinds
Steps are being made in a positive direction, as Pfizer plans to spin off up to 20 percent of its animal health business in an initial public offering (IPO) this August.
Pfizer IPO, Cost Cuts Yield Time to Reinvent Its Research  Bloomberg
Cost-Cutting Helps Pfizer Beat Analysts' Expectations  New York Times
For Pfizer, Boston's medical labs a lure
Pfizer Inc., the world's largest pharmaceutical company, has a storied history of hunting for blockbuster drugs in its own labs.
Pfizer Announces Topline Results Of First Of Four Studies In Bapineuzumab ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC ...
Hopes dim for Alzheimer's trials after Pfizer failure  Reuters
Pfizer-J&J Alzheimer's Drug Fails to Aid Cognition  Bloomberg
Pfizer to return rights to three Acura products
Pfizer Inc will return three products it was developing using Acura Pharmaceuticals Inc's abuse-resistant technology, Acura said on Friday.
Travelers Sues Pfizer For $47M Over Epilepsy Drug
Law360, New York (July 18, 2012, 11:09 PM ET) -- Travelers Indemnity Co. and several of its affiliates on Wednesday filed a $47 million suit against Pfizer Inc. claiming they overpaid for epilepsy drug Neurontin because of its anti-competitive efforts ...
Pfizer Wins Lyrica Patent Ruling
Pfizer said in a written statement: "With this decision, Pfizer will exclusively provide pregabalin as Lyrica to patients through December 30, 2018, in the U.S.
Pfizer Wins Patent Ruling, Exclusive Sales for Lyrica Drug  Bloomberg
UPDATE 1-US court upholds Pfizer's Lyrica patent protection  Reuters
Hikma Beats GSK, Pfizer In Argatroban IP Infringement Row
Law360, New York (July 31, 2012, 7:17 PM ET) -- GlaxoSmithKline PLC and Pfizer Inc. on Tuesday failed to stop Hikma Pharmaceutical Co.